Mahesh V. Patel's most recent trade in Lipocine Inc was a trade of 25,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 25,000 | 182,668 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2025 | 8,629 | 157,668 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Patel V. Mahesh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 16,371 | 149,039 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 10,320 | 132,688 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | V. Mahesh Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 26,691 | 149,039 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 4,893 | 112,311 (0%) | 0% | 0 | Common Stock | |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 5.03 per share. | 25 May 2023 | 8,706 | 107,418 (0%) | 0% | 5.0 | 43,791 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.32 per share. | 24 Mar 2023 | 150,000 | 1,678,090 (3%) | 0% | 0.3 | 48,000 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.33 per share. | 17 Mar 2023 | 50,000 | 1,528,090 (3%) | 0% | 0.3 | 16,500 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 300,000 | 2,542,395 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 112,500 | 2,242,395 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.39 per share. | 14 Nov 2022 | 75,000 | 1,478,090 (3%) | 0% | 0.4 | 29,250 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.41 per share. | 27 Sep 2022 | 100,000 | 1,403,090 (2%) | 0% | 0.4 | 41,000 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.77 per share. | 16 May 2022 | 50,000 | 1,303,090 (2%) | 0% | 0.8 | 38,495 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 287,500 | 287,500 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 1.09 per share. | 18 Nov 2021 | 25,000 | 1,253,090 (2%) | 0% | 1.1 | 27,250 | Common Stock |